KPC-34Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanismsKucera Paper Lipid Nucleoside Conjugates for the Treatment of CancerKucers & Pardee Paper Improving Nucleoside Analogs via Lipid ConjugationShort Summary of KPC34The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for LeukemiaWake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancerDHA-dFdCShort-term Toxicity Study of DHA-dFdCStudy of DHA-dFdCSynthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine ArabinosideGETEmail Alerts.Receive the latest news & events.GO
